Drug Firms Can Share GMP Data From Supplier Audits, FTC Says
This article was originally published in The Pink Sheet Daily
Executive Summary
Rx-360 International Pharmaceutical Supply Chain Consortium plans to share information about the quality and safety of ingredients purchased from common suppliers.
You may also be interested in...
Rx-360 Consortium Aims to Curb Pharmaceutical Supply Chain Threats
Rx-360 Consortium answers the call to develop a global solution to the pharmaceutical supply chain crisis exemplified by last year's heparin adulteration. The consortium, which brings a holistic perspective and a bias for action, will meet June 5 in Washington to chart its course. Its three-year plan calls for adopting and when necessary setting standards, identifying and sharing potential adulteration threats such as the current shortage of acetonitrile, sharing information from audits of suppliers and developing new technologies with the help of research universities. The group envisions a flexible audit-sharing system that could include second- and third-party audits that might be built on an IT platform originally developed to share audits of working conditions.
Cancer-Genomics Firm Quanticel Debuts With Close Ties To Celgene, And An Exit In Mind
Celgene will get exclusive use of Quanticel's single-cell genomic analysis to tweak its clinical pipeline, and it also has exclusive options to acquire the venture-backed start-up.
One Trial Plus Supportive Evidence Is Enough For Hospital-, Ventilator-Acquired Pneumonia Indication, Panel Says
Anti-Infective Drugs Advisory Committee members viewed one-trial as practical means of gaining efficacy data.